The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions.

Hims & Hers Health (NYSE:HIMS) is up ~10% in Monday morning trading following a recent lawsuit challenging the U.S. FDA's  decision to remove Eli Lilly's (NYSE:LLY) tirzepatide from a drug shortages list.